UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 50

Sortiert nach

Identification and characterization of a new autoimmune protein in membranous nephropathy by immunoscreening of a renal cDNA library

PloS one, 2012-11, Vol.7 (11), p.e48845-e48845

2012

Volltextzugriff (PDF)

Proteomic analysis of urine from proteinuric patients shows a proteolitic activity directed against albumin

Nephrology, dialysis, transplantation, 2009-05, Vol.24 (5), p.1672-1681

2009

Volltextzugriff (PDF)

The Role of PEC Progenitors in ADPKD Progression

International journal of stem cells, 2012-05, Vol.5 (1), p.65-72

2012

Volltextzugriff (PDF)

Interstitial fluid obtained from kidney biopsy as new source of renal biomarkers

Journal of nephrology, 2011-05, Vol.24 (3), p.329-337

2011

Volltextzugriff (PDF)

CD133 and CD24 expression in renal tissue of patients affected by autosomal dominant polcystic kidney disease

Stem cell discovery, 2013, Vol.3 (4), p.211-217

2013

Volltextzugriff (PDF)

Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study

Cancers, 2023-07, Vol.15 (14), p.3706

2023

Volltextzugriff (PDF)

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome

Cancer, 2023-06, Vol.129 (11), p.1704-1713

2023

Volltextzugriff (PDF)

Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy

Cancer, 2024-04, Vol.130 (8), p.1270-1280

2024

Volltextzugriff (PDF)

Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study

Cancer, 2024-07

2024

Volltextzugriff (PDF)

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

British journal of haematology, 2021-04, Vol.193 (2), p.356-368

2021

Volltextzugriff (PDF)

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Blood cancer journal (New York), 2021-01, Vol.11 (1), p.4-4, Article 4

2021

Volltextzugriff (PDF)

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Blood, 2022-11, Vol.140 (Supplement 1), p.9688-9690

2022

Volltextzugriff (PDF)

Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis

Blood, 2021-11, Vol.138 (Supplement 1), p.3624-3624

2021

Volltextzugriff (PDF)

P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT‐TERM RUX PROGNOSTIC MODEL (STR‐PM)

HemaSphere, 2023-08, Vol.7 (S3), p.e4692509-n/a

2023

Volltextzugriff (PDF)

First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria

Blood, 2020-11, Vol.136 (Supplement 1), p.43-44

2020

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(48)
Webseiten
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Hematology
(11)
Humans
(10)
Oncology
(9)
Female
(8)
Male
(8)
Ruxolitinib
(7)
Adult
(6)
Aged
(6)
Myelofibrosis
(6)
Survival
(6)
Middle Aged
(5)
Patients
(5)
Toxicity
(5)
Aged, 80 And Over
(4)
Imatinib Mesylate - Administration & Dosage
(4)
Leukemia
(4)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(4)
Treatment Outcome
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Identification and characterization of a new autoimmune protein in membranous nephropathy by immunoscreening of a renal cDNA library

Proteomic analysis of urine from proteinuric patients shows a proteolitic activity directed against albumin

The Role of PEC Progenitors in ADPKD Progression

Interstitial fluid obtained from kidney biopsy as new source of renal biomarkers

CD133 and CD24 expression in renal tissue of patients affected by autosomal dominant polcystic kidney disease

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis

The BCR‐ABL1 transcript type influences response and outcome in Philadelphia chromosome‐positive chronic myeloid leukemia patients treated frontline with imatinib

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome

Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis

P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT‐TERM RUX PROGNOSTIC MODEL (STR‐PM)

First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria

Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome

Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

Suchergebnisse filtern